What is atorvastatin used for?

Indications and Usage, quoted from the label by Mylan Pharmaceuticals Inc. (ANDA091226). Cross-references to other label sections are left out.

Atorvastatin calcium tablets are indicated:

• To reduce the risk of:
• oMyocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD
• oMI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD
• oNon-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD
• As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:
• oAdults with primary hyperlipidemia.
• oAdults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).
• As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).
• As an adjunct to diet for the treatment of adults with:
• oPrimary dysbetalipoproteinemia
• oHypertriglyceridemia

Source: DailyMed label, set id d0a0feb6-84f0-4693-a11f-eb4f7ae0a87d, version 28, effective June 15, 2026. NDC 0378-3950, one of 232 listings for this product.

Indications and Usage, quoted from the label by Apotex Corp. (ANDA090548). Cross-references to other label sections are left out.

Atorvastatin Calcium Tablets are indicated:

• To reduce the risk of:
• Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD
• MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD
• Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD
• As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:
• Adults with primary hyperlipidemia.
• Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).
• As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).
• As an adjunct to diet for the treatment of adults with:
• Primary dysbetalipoproteinemia
• Hypertriglyceridemia

Source: DailyMed label, set id d9adb9e4-c495-9530-e5e3-7e3b01d53e4c, version 35, effective September 8, 2026. NDC 60505-2578, one of 67 listings for this product.